GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

References

• Ramon G. Procédés pour accroître la production des antitoxines. Ann. Inst. Pasteur40, 1–10 (1926).
   Google Scholar
• Glenny AT, Buttle GAH, Stevens MF. Rate of disappearance of diphteria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. J. Pathol.34, 267–275 (1931).
   Google Scholar
• Brewer JM. (How) do aluminium adjuvants work? Immunol. Lett.102(1), 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol.70(6), 849–860 (2001).
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine24(Suppl. 2), S44–S45 (2006).
   Web of Science ®Google Scholar
• Singh M, Carlson JR, Briones M et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine16(19), 1822–1827 (1998).
   PubMed Web of Science ®Google Scholar
• Alving CR, Richards RL, Moss J et al. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. Vaccine4(3), 166–172 (1986).
   PubMed Web of Science ®Google Scholar
• Alving CR, Koulchin V, Glenn GM, Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev.145, 5–31 (1995).
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol.7(3), 179–190 (2007).
   PubMed Web of Science ®Google Scholar
• Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not Toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol.165(10), 5780–5787 (2000).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther.4(7), 1129–1138 (2004).
   PubMed Web of Science ®Google Scholar
• Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin. Investig. Drugs7(9), 1475–1482 (1998).
   PubMedGoogle Scholar
• Garçon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Immunopotentiators in Modern Vaccines. Schijns V, O’Hagan D (Eds). Elsevier Academic Press, London, UK 161–177 (2006).
   Google Scholar
• de Franchis R, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol.39(Suppl. 1), S3–S25 (2003).
   PubMed Web of Science ®Google Scholar
• Tong NKC, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int.68(5), 2298–2303 (2005).
   PubMed Web of Science ®Google Scholar
• Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines6(2), 133–140 (2007).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol.55(4), 244–265 (2002).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health40(6), 564–571 (2007).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364(9447), 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Gall SA, Teixeira J, Wheeler C et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. 98th Annual Meeting of the American Association for Cancer Research. April 14–18 Los Angeles, CA, USA (2007) (Abstract 4900).
   Google Scholar
• Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet369(9580), 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Diefenbach RJ, Miranda-Saksena M et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis.194(Suppl. 1), S11–S18 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein D. Glycoprotein D adjuvant herpes simplex virus vaccine. Expert Rev. Vaccines4(5), 615–627 (2005).
   PubMed Web of Science ®Google Scholar
• Bourne N, Bravo FJ, Francotte M et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis.187(4), 542–549 (2003).
   PubMed Web of Science ®Google Scholar
• Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J. Infect. Dis.192(12), 2117–2123 (2005).
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med.347(21), 1652–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Moore ML, Peebles RS Jr. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics. Pharmacol. Ther.112(2), 405–424 (2006).
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol.89(4), 405–421 (1969).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89(4), 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol.70(5), 2852–2860 (1996).
   PubMed Web of Science ®Google Scholar
• Connors M, Giese NA, Kulkarni AB, Firestone C-Y, Morse HC, III, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol.68(8), 5321–5325 (1994).
   PubMed Web of Science ®Google Scholar
• Prince GA, Denamur F, Deschamps M et al. Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine19(15–16), 2048–2054 (2001).
   PubMed Web of Science ®Google Scholar
• Prince GA, Capiau C, Deschamps M et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J. Virol.74(22), 10287–10292 (2000).
   PubMed Web of Science ®Google Scholar
• Klein E, Kis LL, Klein G. Epstein–Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene26(9), 1297–1305 (2007).
   PubMed Web of Science ®Google Scholar
• Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein–Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev.170, 49–64 (1999).
   PubMed Web of Science ®Google Scholar
• Gu SY, Huang TM, Ruan L et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand.84, 171–177 (1995).
   PubMedGoogle Scholar
• Sokal EM, Hoppenbrouwers K, Vandermeulen C et al. Recombinant gp350 vaccine for infectious mononucleosis: Phase II randomised, double-blind, placebo-controlled trial in healthy young adults to evaluate safety, immunogenicity and efficacy of an Epstein–Barr virus (EBV) vaccine. J. Infect. Dis. (2007) (In Press).
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Kundi M et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine18(20), 2095–2101 (2000).
   PubMed Web of Science ®Google Scholar
• Boland G, Beran J, Lievens M et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine23(3), 316–320 (2004).
   Google Scholar
• Jacques P, Moens G, Desombere I et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine20(31–32), 3644–3649 (2002).
   PubMed Web of Science ®Google Scholar
• Moutschen M, Léonard P, Sokal EM et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults. Vaccine25(24), 4697–4705 (2007).
   PubMed Web of Science ®Google Scholar
• Thoelen S, Van Damme P, Mathei C et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine16(7), 708–714 (1998).
   PubMed Web of Science ®Google Scholar
• Newman MJ, Wu J-Y, Coughlin RT et al. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates. AIDS Res. Hum. Retroviruses8(8), 1413–1418 (1992).
   PubMed Web of Science ®Google Scholar
• Newman MJ, Wu J-Y, Gardner BH et al. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine15(9), 1001–1007 (1997).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med.336(2), 86–91 (1997).
   PubMed Web of Science ®Google Scholar
• Garçon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines2(2), 231–238 (2003).
   PubMedGoogle Scholar
• Doherty JF, Pinder M, Tornieporth N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am. J. Trop. Med. Hyg.61(6), 865–868 (1999).
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis.183(4), 640–647 (2001).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJM, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet358(9297), 1927–1934 (2001).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet364(9443), 1411–1420 (2004).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet366(9502), 2012–2018 (2005).
   PubMed Web of Science ®Google Scholar
• Pinder M, Reece WHH, Plebanski M et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clin. Exp. Immunol.135(2), 286–293 (2004).
   PubMed Web of Science ®Google Scholar
• Epstein JE, Charoenvit Y, Kester KE et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine22(13–14), 1592–1603 (2004).
   PubMed Web of Science ®Google Scholar
• Lalvani A, Moris P, Voss G et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis.180(5), 1656–1664 (1999).
   PubMed Web of Science ®Google Scholar
• Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. J. Immunol.171(12), 6961–6967 (2003).
   PubMed Web of Science ®Google Scholar
• Reece WHH, Pinder M, Gothard PK et al. A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med.10(4), 406–410 (2004).
   PubMed Web of Science ®Google Scholar
• Pichyangkul S, Gettayacamin M, Miller RS et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP142 formulated with novel adjuvants or with alum. Vaccine22(29–30), 3831–3840 (2004).
   PubMed Web of Science ®Google Scholar
• Ockenhouse CF, Angov E, Kester KE et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine24(15), 3009–3017 (2006).
   Google Scholar
• Withers MR, McKinney D, Ogutu BR et al. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized Phase Ib dose-escalation trial in Kenyan children. PLoS Clin. Trials1(7), e32 (2006).
   PubMedGoogle Scholar
• Fine PE. The BCG story: lessons from the past and implications for the future. Rev. Infect. Dis.11(Suppl. 2), S353–S359 (1989).
   PubMedGoogle Scholar
• Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA271(9), 698–702 (1994).
   PubMed Web of Science ®Google Scholar
• Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol.22(6), 1154–1158 (1993).
   PubMed Web of Science ®Google Scholar
• Skeiky YAW, Alderson MR, Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol.172(12), 7618–7628 (2004).
   PubMed Web of Science ®Google Scholar
• Tsenova L, Harbacheuski R, Moreira AL et al. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect. Immun.74(4), 2392–2401 (2006).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O et al. Safety and immunogenicity of the Mtb72f/AS02A tuberculosis vaccine in PPD-negative Belgian adults. Medical and Health in the Tropics. Marseille, France, 11-15 Sept 2005 (Abstract O-036).
   Google Scholar
• Skeiky YAW, Alderson MR, Ovendale PJ et al. Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. Vaccine23(30), 3937–3945 (2005).
   PubMed Web of Science ®Google Scholar
• Langermans JAM, Doherty TM, Vervenne RAW et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine23(21), 2740–2750 (2005).
   PubMed Web of Science ®Google Scholar
• Bienzle U, Günther M, Neuhaus R et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology38(4), 811–819 (2003).
   PubMed Web of Science ®Google Scholar
• Vandepapelière P, Rehermann B, Koutsoukos M et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine23(20), 2591–2601 (2005).
   PubMed Web of Science ®Google Scholar
• Mooij P, van der Kolk M, Bogers WMJM et al. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian–human immunodeficiency virus infection. AIDS12(5), F15–F22 (1998).
   PubMed Web of Science ®Google Scholar
• Voss G, Manson K, Montefiori D et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys using an adjuvanted multicomponent protein vaccine. J. Virol.77(2), 1049–1058 (2003).
   PubMed Web of Science ®Google Scholar
• Goepfert PA, Tomaras GD, Horton H et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine25(3), 510–518 (2007).
   PubMed Web of Science ®Google Scholar
• Marchand M, Punt CJA, Aamdal S et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer39(1), 70–77 (2003).
   PubMed Web of Science ®Google Scholar
• Vantomme V, Dantinne C, Amrani N et al. Immunologic analysis of a Phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J. Immunother.27(2), 124–135 (2004).
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Altorki NK, Stockert E et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol.172(5), 3289–3296 (2004).
   PubMed Web of Science ®Google Scholar
• Polhemus ME, Magill AJ, Cummings JF et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine25(21), 4203–4212 (2007).
   PubMed Web of Science ®Google Scholar
• Thera MA, Doumbo OK, Coulibaly D et al. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a Phase I randomized trial. PLoS Clin. Trials1(7), e34 (2006).
   PubMedGoogle Scholar
• Macete E, Aponte JJ, Guinovart C et al. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique. Trop. Med. Int. Health12(1), 37–46 (2007).
   PubMed Web of Science ®Google Scholar
• Stewart VA, McGrath SM, Davis S et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine24(42–43), 6483–6492 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart VA, McGrath SM, Dubois PM et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun.75(5), 2283–2290 (2007).
   PubMed Web of Science ®Google Scholar
• Brando C, Ware LA, Freyberger H et al. Murine immune responses to liver stage antigen-1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Infect. Immun.75(2), 838–845 (2007).
   PubMed Web of Science ®Google Scholar
• Reed S, Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes. Infect.7(5–6), 922–931 (2005).
   PubMed Web of Science ®Google Scholar